Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Ductal Carcinoma in Situ
Interventions: Black cohosh; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Melanoma (Skin)
Interventions: therapeutic autologous dendritic cells; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Early Triple Negative Breast Cancer
Interventions: Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin (hydrochloride), Boserolimab, Epirubicin Hydrochloride, Cyclophosphamide, Capecitabine, Olaparib (if approved/available locally); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
Interventions: NM32-2668; Biological
Lead sponsor: Numab Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions: Molecular Breast Imaging, Screening Mammography; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Depression, Breast Cancer, Stress, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions: Videoconferencing support group; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Hereditary Angio Edema
Interventions: OCTA-C1-INH, Placebo; Drug · Other
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio

Conditions: Erythema
Interventions: DuraporeTM and Hy-Tape®; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Dermatitis
Interventions: Sulforaphane-containing broccoli sprout extracts (active agent), Vehicle (inactive control); Other · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Obesity
Interventions: dietary intervention; Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Radiation, Lumpectomy/Mastectomy, Veliparib; Radiation · Procedure · Drug
Lead sponsor: Richard Zellars; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 6
States / cities: Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana

Conditions: Psoriasis
Interventions: RA-18C3; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 84 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mastectomy, Breast Cancer
Interventions: Liposomal bupivacaine, Standard bupivacaine, Placebo; Drug · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Lapatinib, Doxorubicin, Cyclophosphamide, Docetaxel, Pegfilgrastim, Filgrastim, Dexamethasone, Trastuzumab; Drug
Lead sponsor: George Albert Fisher; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Sedentary, Skin Cancer
Interventions: Tailored Internet Communication with Relational Agent, Tailored Internet Communications; Other
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,364 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Kingston, Rhode Island

Conditions: Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms
Interventions: INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 2,748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Birmingham, Alabama • Los Angeles, California • Oklahoma City, Oklahoma

Conditions: Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions: Santyl, Control; Biological · Procedure
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Phoenix, Arizona • Tucson, Arizona • Southfield, Michigan + 3 more

Conditions: Venous Leg Ulcer
Interventions: EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 17 more

Conditions: Solid Tumors
Interventions: INCB001158, Epacadostat, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Breast Neoplasms
Interventions: Afatinib once daily (OD), Vinorelbine Weekly; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Interventions: Aldesleukin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 1 more

Conditions: Atopic Dermatitis
Interventions: Fluocinonide; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Atopic Dermatitis, Eczema Herpeticum, Herpes Simplex Infections, Eczema Vaccinatum
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Molecular Breast Imaging in Women With Atypia and LCIS

Expanding Rural Access: Distance Delivery of Support Groups (Main Study)

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Durapore vs. Hy-Tape to Secure The Endotracheal Tube

Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis

A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women

Pre-Operative Radiation and Veliparib for Breast Cancer

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Prospective Radiologic Evaluation of Changes Following Fat Grafting

Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Online Tailored Interventions & Relational Agents for Exercise and Sun Protection

INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

Using Santyl on Diabetic Foot Ulcers

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

VANOS Cream and Skin Barrier Function

Interferon Responses in Eczema Herpeticum